Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vudalimab + carboplatin + cabazitaxel
- Development stage
- Unknown
- Lead developer
- Xencor
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is an experimental combination regimen of three anticancer agents: **vudalimab** (also known as XmAb20717, a bispecific monoclonal antibody targeting PD-1 and CTLA-4), **carboplatin** (a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis), and **cabazitaxel** (a semi-synthetic taxane chemotherapy, primarily used in metastatic castration-resistant prostate cancer, functioning as a microtubule inhibitor). This combination is investigated in various advanced or metastatic malignancies, especially genitourinary cancers such as metastatic castration-resistant prostate cancer (mCRPC), within clinical trials.
- Brand names
- Jevtana (for cabazitaxel)none for vudalimabnone for carboplatin as a brand
- Other names
- vudalimab + carboplatin + cabazitaxelXmAb20717 + carboplatin + cabazitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vudalimab + carboplatin + cabazitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vudalimab + carboplatin + cabazitaxel.